What is it about?
Newly available treatment for late-onset Pompe disease
Featured Image
Photo by Blogging Guide on Unsplash
Why is it important?
review of a therapy approved by both the FDA and European regulatory agencies
Perspectives
May patients on ERT will switch to this newly available drug
Prof Corrado Angelini
Universita degli Studi di Padova Polo Bibliotecario di Scienze Farmacologia e Scienze Farmaceutiche
Read the Original
This page is a summary of: Evaluating avalglucosidase alfa for the management of late-onset Pompe disease, Expert Review of Neurotherapeutics, January 2024, Taylor & Francis,
DOI: 10.1080/14737175.2024.2306855.
You can read the full text:
Contributors
The following have contributed to this page
